AbbVie Strengthens Evidence For Rinvoq In Crohn's
Executive Summary
Over 10 datasets presented at Digestive Disease Week strengthen the case that clinicians should view AbbVie’s selective JAK inhibitor Rinvoq as a powerful addition to their clinical toolbox for moderate-to-severe Crohn’s disease patients. However, safety concerns will keep it as second-line treatment in the US after its likely label expansion this month.
You may also be interested in...
Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking
Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.
NVIDIA Extends Its Biopharma Tentacles
NVIDIA is further embedding itself in the biopharma industry. Its artificial intelligence tools are now more accessible, integrated and it is taking a strategic collaborative approach with competitors like Google to bolster AI-driven startups that ultimately use its tools.
Glioblastoma Market Snapshot: Two Approvals In 2024 And A Rich Pipeline
Glioblastoma carries a grim prognosis. The biopharma industry is trying to improve patient outcomes, with 120 drugs in the pipeline and two anticipated approvals this year.